Since they are now the only successful therapy approach among the currently available anti-AD medications, physicians mostly rely on these acetylcholinesterase inhibitors, such as galantamine (alkaloid) and rivastigmine (polyphenol), that have the ability to scavenge free radicals, which lowers oxidative stress, and they subsequently decrease neurodegeneration and inflammatory processes that are mediated by free radicals [22]. This evidence concerns the gene ACHE and Alzheimer disease.